Улога на метаболичниот синдром во развој и прогресија на хроничната бубрежна слабост

Tatjana Barjaktarova Prosheva, Liljana Tozija

Извадок


Метаболичкиот синдром станува се поголем здравствен проблем во светот, како во земјите во развој така и во високо развиените земји. Познато е дека компонентите на метаболичкиот синдром (обезност, хипертензија, хиперлипидемија и инсулинска резистенција) ја зголемуваат инциденцата, а со тоа и морбидитетот и морталитетот на кардиоваскуларните заболувања. Постојат студии кои укажуваат и на асоцијација на метаболичкиот синдром со развојот и прогресијата на хроничната бубрежна болест. Корелацијата на поединечните ентитети на метаболичкиот синдром како што е хипертензијата и инсулинската резистенција со последователен развој на тип 2 дијабетес мелитус, со развојот на хроничната бубрежна слабост е добро позната, но сеуште има дилеми и се дискутира за ефектот на метаболичкиот синдром како целина врз нарушувањето на бубрежната функција. Во можните механизми кои ја оштетуваат бубрежната функција се вбројуваат инсулинската резистенција и оксидативниот стрес, микроваскуларното оштетување и исхемја на бубрезите.

Целта на овој прегледен труд е да се систематизираат податоците добиени од студиите кои укажуваат на поврзаност на овие две патолошки состојби за подобро да се разбере како компонентите на метаболичкиот синдром влијаат на прогресијата на хроничната бубрежна болест, намалувањето на гломеруларната филтрациона рата и патофизиолошките промени на бубрезите асоцирани со метаболички синдром.

Во трудот се опфатени понови сознанија и наоди и нивна примена во третманот на метаболичкиот синдром асоциран со ХББ што вклучува редукција на телесна тежина, промена на животниот стил со соодветно модифицирана диета и физичка активност.

Клучни зборови


Метаболички синдром; хронична бубрежна болест; обезност; инсулинска резистенција; хипертензија; дислипидемија

Комплетен текст:

PDF [Macedonian] (English)

References


Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607.

Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989;149(7):1514-20.

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421.

Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–438.

Alberti KG, Zimmet P, Shaw J. The metabolic syndrome--a new worldwide definition. Lancet. 2005;366:1059–1062.

World Health Organisation. Energy and protein requirements. Report of a joint FAO/WHO/UNU expert consultation. Geneva, Switzerland: World Health Organisation;. WHO Technical Report Series, 1985: 724.

Obunai K, Jani S, Dangas GD. Cardiovascular morbidity and mortality of the metabolic syndrome. Med Clin North Am. 2007;91(6):1169–1184.

Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28:1769–1778.

Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu W, Howard BV. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart Study. Diabetes Care. 2003;26:861–867.

Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722–728.

Lin WY, Liu CS, Li TC, Lin T, Chen W, Chen CC, Li CI, Lin CC. In addition to insulin resistance and obesity, hyperuricemia is strongly associated with metabolic syndrome using different definitions in Chinese populations: a population-based study (Taichung Community Health Study) Ann Rheum Dis. 2008;67:432–433.

Ford ES. Prevalence of the metabolic syndrome defied by the International Diabetes Federation among adults in the US Diabetes Care. 2005;28:2745-2749.

Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356–359.

Nashar K, Egan BM. Relationship between chronic kidney disease and metabolic syndrome: current perspectives. Diabetes Metab Syndr Obes. 2014; 7:421-35.

Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003–2006. Natl Health Stat Report. 2009;13: 1–7.

Kidney Disease: Improving Gobal Outcomes (KDIGO) CKD Work Group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Supp. 2013;3(1):1–150.

Kurella M, Lo JC, Chertow GM.: Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16: 2134–2140.

Brown WW, Peters RM, Ohmit SE, et al. Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases.2003;42(1):22–35.

Gelber RP, Kurth T, Kausz AT, et al. Association between body mass index and CKD in apparently healthy men. American Journal of Kidney Diseases. 2005;46(5):871–880.

Kramer H, Luke A, Bidani A, Cao G, Cooper R, McGee D. Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. American Journal of Kidney Diseases. 2005;46(4):587–594.

Stengel B, Tarver-Carr ME, Powe NR, Eberhardt MS, Brancati FL. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology. 2003;14(4):479–487.

Rasouli N, Kern PA. Adipocytokines and the Metabolic Complications of Obesity. The Journal of Clinical Endocrinology and Metabolism. 2008;93(11 Suppl 1):S64-S73.

Chiu HK, Tsai EC, Juneja R, Stoever J, Brooks-Worrell B, Goel A, Palmer JP. Equivalent insulin resistance in latent autoimmune diabetes in adults (LADA) and type 2 diabetic patients. Diabetes Res Clin Pract. 2007;77(2):237-44.

Reaven GM. Role of Insulin Resistance in Human Disease. Diabetes. 1988;37:12 1595-1607.

Qu H-Q, Li Q, Rentfro AR, Fisher-Hoch SP, McCormick JB. The Definition of Insulin Resistance Using HOMA-IR for Americans of Mexican Descent Using Machine Learning. PLoS ONE. 2011;6(6):e21041.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9.

Landin K, Krotkiewski M, Smith U. Importance of obesity for the metabolic abnormalities associated with an abdominal fat distribution. Metabolism. 1989;38:572-576.

Després JP1, Tremblay A, Pérusse L, Leblanc C, Bouchard C. Abdominal adipose tissue and serum HDL-cholesterol: association independent from obesity and serum triglyceride concentration. Int J Obes. 1988;12(1):1-13.

Hoehner CM, Greenlund KJ, Rith-Najarian S, Casper ML, McClellan WM. Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. The Inter-Tribal Heart Project. J Am Soc Nephrol. 2002;13(6):1626–1634.

Chen J, Muntner P, Hamm LL, et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol. 2003;14(2):469–477.

Li Y, Xie D, Qin X, Tang G, Xing H, Li Z, Xu X, Xu X, Hou F. Metabolic syndrome, but not insulin resistance, is associated with an increased risk of renal function decline. Clin Nutr. 2015;34(2):269-75.

Hager SR. Insulin resistance of uremia. Am J Kidney Dis. 1989;14(4):272–276.

DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin resistance in uremia. J Clin Invest. 1981;67(2):563–568.

Kobayashi S, Maesato K, Moriya H, Ohtake T, Ikeda T. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis. 2005;45(2):275–280.

Kershaw EE, Flier JS. Adipose Tissue as an Endocrine Organ. J Clin Endocrinol Metab. 2004; 89(6):2548–2556.

Nitta K. Possible link between metabolic syndrome and chronic kidney disease in the development of cardiovascular cisease. Cardiol Res Pract. 2011;2011:963517.

Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis. 2002;39(1):1–11.

Williams KW, Scott MM, Elmquist JK. From observation to experimentation: leptin action in the mediobasal hypothalamus. Am J Clin Nutr. 2009;89(3):985S-990S.

Weigle DS, Duell PB, Connor WE, Steiner RA, Soules MR, Kuijper JL. Effect of fasting, refeeding, and dietary fat restriction on plasma leptin levels. J. Clin. Endocrinol. Metab. 1997;82(2): 561–5.

Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int. J. Obes. Relat. Metab. Disord. 2002;26(11): 1407–1433.

Kim HJ, Vaziri ND, Norris K, An WS, Quiroz Y, Rodriguez-Iturbe B. High-calorie diet with moderate protein restriction prevents cachexia and ameliorates oxidative stress, inflammation and proteinuria in experimental chronic kidney disease. Clin Exp Nephrol. 2010;14(6):536–547.

Abou-Youssef H, Kholoussi S, Ishak M, Kholoussi N, Zahraa Ahmed El. Estimation of resistin in chronic kidney disease. Archive of Hellenic Medicine: ISSN 1105-3992

Cawthorn WP, Scheller EL, Learman BS, Parlee SD, Simon BR, Mori H, Ning X, Bree AJ, Schell B, Broome DT, Soliman SS, DelProposto JL, Lumeng CN, Mitra A, Pandit SV, Gallagher KA, Miller JD, Krishnan V, Hui SK, Bredella MA, Fazeli PK, Klibanski A, Horowitz MC, Rosen CJ, MacDougald OA. Bone marrow adipose tissue is an endocrine organ that contributes to increased circulating adiponectin during caloric restriction. Cell Metab. 2014;20(2):368-75.

Scheller EL, Rosen CJ. What’s the matter with MAT? Marrow adipose tissue, metabolism, and skeletal health. Annals of the New York Academy of Sciences. 2014;1311(1):14-30.

Renaldi O, Pramono B, Sinorita H, Purnomo LB, Asdie RH, Asdie AH. Hypoadiponectinemia: a risk factor for metabolic syndrome. Acta Med Indones. 2009;41(1): 20–4.

Becker B, Kronenberg F, Kielstein JT, et al. MMKD Study Group Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol. 2005;16(4):1091–1098.

Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2002;13(1):134–141.

Manrique C, Lastra G, Gardner M, Sowers JR. The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med Clin North Am. 2009;93(3):569–582.

Rashidi A, Ghanbarian A, Azizi F. Are patients who have metabolic syndrome without diabetes at risk for developing chronic kidney disease? Evidence based on data from a large cohort screening population. Clin J Am Soc Nephrol. 2007;2(5):976–983.

Wang C, Blough ER, Arvapalli R, et al. Metabolic syndrome-induced tubulointerstitial injury: role of oxidative stress and preventive effects of acetaminophen. Free Radic Biol Med. 2013;65:1417–1426.

Hallan S, de Mutsert R, Carlsen S, Dekker FW, Aasarød K, Holmen J. Obesity, smoking, and physical inactivity as risk factors for CKD: are men more vulnerable? Am J Kidney Dis. 2006;47(3):396–405.

Finkelstein J, Joshi A, Hise MK. Association of physical activity and renal function in subjects with and without metabolic syndrome: a review of the Third National Health and Nutrition Examination Survey (NHANES III) Am J Kidney Dis. 2006;48(3):372–382.

Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144(1):21–28.

54. Bolignano D1, Zoccali C. Effects of weight loss on renal function in obese CKD patients: a systematic review. Nephrol Dial Transplant. 2013 Nov;28 Suppl 4:iv82-98.

Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59(1):260–269.

Tonelli M, Wanner C. Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann Intern Med. 2014;160(3):182.

Kitiyakara C, Yamwong S, Cheepudomwit S, et al. The metabolic syndrome and chronic kidney disease in a Southeast Asian cohort. Kidney Int. 2007;71(7):693–700.

Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011;6(10):2364–2373.

Lea JP, Greene EL, Nicholas SB, Agodoa L, Norris KC. Cardiorenal metabolic syndrome in the African diaspora: rationale for including chronic kidney disease in the metabolic syndrome definition. Ethn Dis. 2009;19(2 Suppl 2):S2–S11.

Gluba A, Mikhailidis DP, Lip GY, Hannam S, Rysz J, Banach M. Metabolic syndrome and renal disease. Int J Cardiol. 2013;164(2):141–150.

Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific Statement. Circulation. 2005;112(17):2735–2752.




DOI: http://dx.doi.org/10.3889/mmej.2015.50005

Метрика на труд

Внесува метрика ...

Metrics powered by PLOS ALM

Refbacks



Печатарски права (c) 2015 Татјана Бајрактарова Прошева, Лилјана Тозија

##submission.license.cc.by-nc-nd4.footer##



Издавач: АјДи Дизајн 2012/ДООЕЛ Скопје, Република Македонија